(Q41009303)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Martijn A H Oude Voshaar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Martinus A F J van de Laar

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

1 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

82 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

eS2-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

Gout: why is this curable disease so seldom cured?

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

1 reference

7 January 2021

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Does colchicine work? The results of the first controlled study in acute gout.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Difficult-to-treat gouty arthritis: a disease warranting better management

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Acute inflammatory arthritis: interleukin-1 blockade: a magic wand for gout?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The pathogenesis of bone erosions in gouty arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Prevalence and incidence of the diagnosis of gout in Great Britain

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The prevalence and prophylaxis of gout in England

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Prevalence of gout with comorbidity aggregations in southern Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout is on the increase in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Systematic review of the prevalence of gout and hyperuricaemia in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

New developments in the epidemiology and genetics of gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Incidence and risk factors for gout in white men.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Revisiting comorbidities in gout: a cluster analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The role of hyperuricemia in vascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Pain patterns in the rheumatic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20)

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Perceptions of disease and health-related quality of life among patients with gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Is gout associated with reduced quality of life? A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR).

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Quality of life and disability in patients with treatment-failure gout.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

A literature review of the epidemiology and treatment of acute gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

A revised estimate of the burden of illness of gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Gout in the elderly--a population health study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Cost of illness and determinants of costs among patients with gout.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The economic burden of gout on an employed population.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Healthcare burden of in-hospital gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Evaluation of health care costs and utilization patterns for patients with gout

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The impact of gout on work absence and productivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2815%2930002-6

7 January 2021

10.1016/S1297-319X(15)30002-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26717799%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference